Navigation Links
Study in Circulation provides detail on how low blood flow promotes vascular disease
Date:6/23/2008

sel walls. The current study unites the three discoveries by providing strong evidence that cyclophilin A, a protein involved in the immune response, has dual roles in vascular disease. It recruits immune cells that cause inflammation, and it drives pathogenic growth and remodeling, when triggered by reactive oxygen species in diseased blood vessels.

"For years researchers worldwide have sought to determine exactly how low blood flow and the immune reaction to cholesterol deposits, along with the reactive oxygen species created by both, drive the progression of atherosclerosis," said Bradford C. Berk, M.D., Ph.D., professor of Medicine in the Aab Cardiovascular Research Institute within the University of Rochester Medical Center, and senior author of the study. "We are tremendously excited by these results because they provide solid evidence that cyclophilin A is at the center of it all."

Study Details

The study results reflect blood vessel anatomy. Blood flows through the innermost part of a vessel called the lumen. The inside of that inner tube is lined with a layer of endothelial cells, which is surrounded by the fibrous cells of the intima, which is surrounded by a layer of smooth muscle cells in the media. Many blood vessels are muscular because the flexing of such muscle helps to control blood flow (blood pressure).

To examine the reaction of CyPA signaling to the overproduction of reactive oxygen species, Berk's team genetically engineered one group of mice to produce less CyPA, another group to make more, and compared both groups to "normal" mice as all three groups experienced reduced blood flow in the carotid artery. Reduced blood flow increased CyPA expression in the vascular wall, and promoted the migration of smooth muscle cells into the intima, where they began to grow (proliferate) and contribute to the formation of atherosclerotic lesions. Reduced flow, and the related increase in CyPA signaling, also c
'/>"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Study shows that chronic grief activates pleasure areas of the brain
2. Researchers seek children for a study of antibiotics for a urinary tract disorder
3. NIH funds highway pollution and health study in Boston, Somerville
4. Study links vitamin D to colon cancer survival
5. Study: Medicare Competitive Bidding Program Could Impede Seniors Access to Diabetes Testing Supplies
6. Study finds Childrens Hospital patient safety program improves caregiver/family communications
7. Study Shows Mothers Who Take Chlorella Boost Babies Antibodies During Breast Feeding
8. Sprinters closest to starter pistol have advantage over those farther away, says study
9. Study indicates grape seed extract may reduce cognitive decline associated with Alzheimers disease
10. Study Ties Herpes Virus to Emerging Form of Diabetes
11. Study underway to find an alternative cure for Crohns disease and ulcerative colitis
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6More Swine Flu Vaccine Coming Soon 60183 1More Swine Flu Vaccine Coming Soon 60183 2More Swine Flu Vaccine Coming Soon 60183 3Highmark Recognized as One of Americas Healthiest Companies 60178 1Highmark Recognized as One of Americas Healthiest Companies 60178 2Anthem Blue Cross and Blue Shield in Missouri Earns NCQA Accreditation Status of Excellent 60173 1Anthem Blue Cross and Blue Shield in Missouri Earns NCQA Accreditation Status of Excellent 60173 2